Abstract
L. Bianchi reports personal fees from speaker and as consultant for AbbVie, Novartis, Janssen-Cilag, Pfizer, UCB and Leo Pharma, outside the submitted work. SP Cannavò has served as speaker or board member for AbbVie, Celgene, Eli Lilly, Leo Pharma, Janssen, Novartis and Sanofi Genzyme. A. Chiricozzi served as advisory board member and consultant and has received fees and speaker's honoraria or has participated in clinical trials for AbbVie, Almirall, Biogen, Fresenius Kabi, Leo Pharma, Lilly, Janssen, Novartis, Sanofi Genzyme and UCB Pharma. A. Conti served as advisory board member and consultant, and has received fees and speaker’s honoraria or has participated in clinical trials for AbbVie, Leo Pharma, Eli Lilly, Novartis, UCB Pharma, Pfizer, Sandoz, Celgene, Biogen and Janssen-Cilag. M.C. Fargnoli has served on advisory boards, received honoraria for lectures and research grants from Almirall, AbbVie, Galderma, Leo Pharma, Mylan, Medac Pharma, Celgene, Pierre Fabre, UCB, Eli Lilly, Pfizer, Janssen, Novartis, Sanofi Genzyme, Roche, Sun Pharma and MSD. P. Gisondi has been a consultant and/or speaker for AbbVie, Almirall, Celgene, Janssen, Leo pharma, Eli Lilly, Novartis, Pfizer, Sandoz and UCB. K. Peris reports personal fees for advisory board meeting from Almirall, AbbVie, Biogen, Janssen, Eli Lilly, Celgene, Galderma, Leo Pharma, Novartis, Pierre Fabre, Sanofi, Sandoz and Sun Pharma outside the conduct of the work. I. Zalaudek has been a consultant and/or speaker for Novartis, Celgene and Amgen.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the European Academy of Dermatology and Venereology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
